论文部分内容阅读
诺华公司治疗肠应激综合征 (ＩＢＳ)药物替加色罗 (ｔｏｇａｓｅｒｏｄ ,Ｚｅｌｍａｃ/Ｚｅｌｎｏｒｍ )的首批临床资料公布 ,在治疗功能性消化不良方面完全可以代替杨森公司因受到广泛质疑而停用的西沙必利。 2 0 0 2年 5月在旧金山消化系统疾病会议上发布的Ⅱ期临床试验初步
The first clinical data from Novartis’s company to treat irritable bowel syndrome (IBS) drug togaserod (Zelmac / Zelnorm) is a complete replacement for Janssen in the widely questioned treatment of functional dyspepsia Cisapride. Preliminary Phase II clinical trial released at San Francisco Conference on Digestive Diseases in May 2002